Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Evaluation of folic acid supplementation by concomitant administration of ethinyl estradiol plus levonorgestrel in healthy female subjects

Texto completo
Autor(es):
Jacob, Juliana de Moraes [1, 2] ; Antunes, Natalicia de Jesus [1] ; Moreno, Ronilson [1] ; De Nucci, Gilberto [1]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] State Univ Campinas UNICAMP, Fac Med Sci, Dept Pharmacol, Alexander Flemming St 105, BR-13083881 Campinas, SP - Brazil
[2] Fed Univ Triangulo Mineiro UNITRI, Uberaba, MG - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS; v. 57, n. 6, p. 290-297, JUN 2019.
Citações Web of Science: 0
Resumo

Objectives: Folic acid supplementation prevents 50 - 75% of cases of neural tube defects. This study evaluated the folic acid supplementation after oral administration of the ethinyl estradiol 0.02 mg + levonorgestrel 0.10 mg + folic acid 0.4 mg coated tablet as well as its safety and tolerability in healthy female subjects. Materials and methods: 36 healthy female subjects received 1 coated tablet of the test product - ethinyl estradiol 0.02 mg + levonorgestrel 0.10 mg + folic acid 0.4 mg for 21 days and a placebo coated tablet containing folic acid 0.4 mg only on the last 7 days of the cycle, in 3 cycles. Blood samples were collected to quantify folate by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The safety was assessed by recording adverse events, monitoring of vital signs, and the evaluation of laboratory tests and ECG. Results: The mean whole blood level of folic acid at baseline (1st day of 1St cycle) was 42.7 +/- 22.2 ng/mL, while on the 28th day of the 3rd cycle it was 47.6 +/- 20.1 ng/mL, with a variation of 11.32%. The subjects tolerated the clinical protocol well and reported no clinically significant adverse effects. Conclusion: Oral contraceptives may be a good vehicle for folate supplementation in women of reproductive age. (AU)

Processo FAPESP: 16/22506-1 - Metabolismo do dapaconazol
Beneficiário:Natalícia de Jesus Antunes
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado